Impact of 18F-FDG PET/CT on treatment of patients with differentiated thyroid carcinoma, negative 131I whole body scan and elevated serum thyroglobulin | ||
| Asia Oceania Journal of Nuclear Medicine and Biology | ||
| مقاله 3، دوره 10، شماره 1، فروردین 2022، صفحه 20-27 اصل مقاله (1.11 M) | ||
| نوع مقاله: Original Article | ||
| شناسه دیجیتال (DOI): 10.22038/aojnmb.2021.58276.1406 | ||
| نویسندگان | ||
| Raef R Boktor1، 2، 3؛ Sze Ting Lee1، 2، 3؛ Salvatore U Berlangieri1؛ Andrew M Scott* 1، 2، 3، 4 | ||
| 1Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC Australia | ||
| 2Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia | ||
| 3School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia | ||
| 4Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia | ||
| چکیده | ||
| Objective(s): 18F-FDG PET/CT is increasingly performed in patients with differen-tiated thyroid cancer. The aim of this study was to assess the clinical impact of 18F-FDG PET/CT on the management of patients with differentiated thyroid carcinoma who had elevated serum thyroglobulin (Tg) and negative 131I whole body scan (WBS). Methods: 67 patients with differentiated thyroid carcinoma were included in this study. The findings of 18F-FDG PET/CT imaging were compared with histo-pathology, follow up imaging, or clinical follow-up results. The diagnostic accuracy of 18F-FDG PET/CT was evaluated for the entire patient group and for those patients with stimulated serum thyroglobulin levels of less than 5, 5–10, and more than 10 pmol/L as well as for local recurrences and metastases sites. The impact of 18F-FDG PET/CT on therapeutic management was also evaluated. Results: 30/67 patients had positive findings on 18F-FDG PET/CT; 28 were true-positive and 2 were false-positive. 18F-FDG PET/CT results were true-negative in 36 patients and false-negative in 1 patient. The overall sensitivity, specificity, accuracy, PPV and NPV of 18F-FDG PET/CT were, 96.5%, 94.5%, 95.5%, 93.3%, and 97.2% respectively. Positive 18F-FDG PET/CT findings were directly correlated with stimulated serum thyroglobulin levels, 7.1% had Tg between 5–10, and 92.9% had Tg greater than 10 pmol/L. 18F-FDG PET/CT had a high or moderate impact on treatment management in 28 (41.8%) of patients. Conclusion: 18F-FDG PET/CT is able to improve diagnostic accuracy and have management impact in a therapeutically relevant way in patients with differentiated thyroid carcinoma who present with rising thyroglobulin level, negative 131I WBS, and clinical suspicion of recurrent disease. | ||
| کلیدواژهها | ||
| FDG PET؛ Thyroglobulin؛ 131I؛ Thyroid carcinoma | ||
| مراجع | ||
|
| ||
|
آمار تعداد مشاهده مقاله: 1,757 تعداد دریافت فایل اصل مقاله: 708 |
||